For instance, AFP is commonly used as a serum biomarker in the management of patients.[10] However, it is important to note that approximately 30% of patients with HCC are AFP‐negative.[11] Therefore, there is an urgent need to develop reliable and novel noninvasive biomarkers that can accurately diagnose and predict the prognosis of HCC. The gene discussed is AFP; the disease is hepatocellular carcinoma.